We have a diversified and balanced portfolio covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
Compound |
Mechanism of action |
Target indication |
Status |
More Information |
PIVLAZ® |
Endothelin receptor antagonist |
Cerebral vasospasm associated with |
Commercially available in Japan |
|
QUVIVIQ™ (daridorexant) |
Dual orexin receptor antagonist |
Insomnia |
Commercially available in the US and the first countries in Europe; |
|
Aprocitentan* |
Dual endothelin receptor antagonist |
Difficult-to-control (resistant) hypertension |
NDA submitted in the US, MAA submitted in the EU, other filings in preparation |
|
Lucerastat |
Glucosylceramide synthase inhibitor |
Fabry disease |
Phase 3 primary endpoint not met, Open Label Extension study (OLE) ongoing |
|
Selatogrel |
P2Y12 inhibitor |
Suspected acute myocardial infarction |
Phase 3 recruiting |
|
Cenerimod |
S1P1 receptor modulator |
Systemic lupus erythematosus |
Phase 3 recruiting |
Investor webcast |
ACT-1004-1239 |
ACKR3 / CXCR7 antagonist |
Multiple sclerosis and other demyelinating diseases |
Phase 2 in preparation |
|
Sinbaglustat |
GBA2/GCS inhibitor |
Rare lysosomal storage disorders |
Phase 1 complete |
|
ACT-1014-6470 |
C5aR1 antagonist |
Immune-mediated disorders |
Phase 1 |
|
ACT-777991 |
CXCR3 antagonist |
Recent-onset Type 1 diabetes |
Phase 1 |
|
IDOR-1117-2520 |
Undisclosed |
Immune-mediated disorders |
Phase 1 |
* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide
Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 was investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy. The study did not meet the primary endpoint. ACT-709478 was generally well tolerated. Neurocrine continues to analyze the data generated in the study.
Innovation fact sheet
For investors, we provide more information on how Idorsia is innovating to change treatment paradigms in our innovation fact sheet. Please visit the investor section for more information.